Davis Clare, Heath Alan, Best Susan, Hewlett Indira, Lelie Nico, Schuurman Rob, Holmes Harvey
Division of Retrovirology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK.
J Virol Methods. 2003 Jan;107(1):37-44. doi: 10.1016/s0166-0934(02)00187-8.
Many laboratories use working reagents/run controls to monitor the performance of their nucleic acid amplification techniques (NAT) for the measurement of HIV-1 RNA. A collaborative study was carried out in order to calibrate seven internationally available working reagents, QC105 (National Serology Reference Laboratory [NRL], Australia), B5 and B10 (Center for Biological Evaluation and Research [CBER], USA), Pelispy (Central Laboratory of the Netherlands Blood Transfusion Service [CLB], The Netherlands), PWS-1 and PWS-3 (National Institute for Biological Standards and Control [NIBSC], UK) and IRC (Virology Networks [VN], The Netherlands) against the 1st International Standard for HIV-1 RNA (code 97/656). Twenty-one laboratories from 12 different countries participated in the collaborative study and from the results it was determined that QC105 contained 4.0 log(10) International Units (IU)/ml, B5 2.2 log(10) IU/ml, B10 3.8 log(10) IU/ml, Pelispy 4.4 log(10) IU/ml, PWS-1 3.6 log(10) IU/ml, PWS-3 2.7 log(10) IU/ml and IRC 4.3 log(10) IU/ml. The seven working reagents calibrated in this international study may be used to validate and standardise the large number of qualitative and quantitative, commercial and in-house NAT assays that are currently being applied in the fields of blood safety and patient management. They will also help laboratories to comply with the sensitivity requirements that may be brought in by the regulatory authorities and may contribute to further harmonisation of guidelines on NAT published by organisations such as the European Medicines Evaluation Agency (EMEA), Paul-Ehrlich Institute and CBER, FDA.
许多实验室使用工作试剂/运行对照来监测其用于检测HIV-1 RNA的核酸扩增技术(NAT)的性能。开展了一项合作研究,以针对第1国际标准HIV-1 RNA(编号97/656)校准七种国际上可获得的工作试剂,即QC105(澳大利亚国家血清学参考实验室[NRL])、B5和B10(美国生物制品评估和研究中心[CBER])、Pelispy(荷兰血液输血服务中心中央实验室[CLB],荷兰)、PWS-1和PWS-3(英国国家生物制品标准与控制研究所[NIBSC])以及IRC(荷兰病毒学网络[VN])。来自12个不同国家的21个实验室参与了这项合作研究,根据结果确定QC105含有4.0 log(10)国际单位(IU)/ml,B5为2.2 log(10) IU/ml,B10为3.8 log(10) IU/ml,Pelispy为4.4 log(10) IU/ml,PWS-1为3.6 log(10) IU/ml,PWS-3为2.7 log(10) IU/ml,IRC为4.3 log(10) IU/ml。在这项国际研究中校准的这七种工作试剂可用于验证和标准化目前在血液安全和患者管理领域应用的大量定性和定量、商业和内部NAT检测方法。它们还将帮助实验室符合监管当局可能提出的灵敏度要求,并可能有助于进一步统一欧洲药品评估局(EMEA)、保罗·埃利希研究所和CBER、美国食品药品监督管理局(FDA)等组织发布的关于NAT的指南。